Leadership & Pay ·
CEO Dr. Lynn Kirkpatrick steps down as CEO to become COO; President James Morrisson takes over
ENSCEnsysce Biosciences, Inc.
Ensysce Biosciences announced that CEO Dr. Lynn Kirkpatrick will relinquish her title and assume the role of Chief Operating Officer immediately following the annual meeting on December 14, 2026. Concurrently, President James Morrisson will succeed her as Chief Executive Officer. Director Will Chang intends to resign after the same meeting. The filing includes an amendment to Dr. Kirkpatrick's employment agreement confirming that the transition does not trigger severance obligations. Ensysce Biosciences is a clinical-stage biopharmaceutical company developing novel pain therapies and overdose protection compounds.